Search Results for keywords:"Foreign-Trade Zone 49"

Merck, Sharp & Dohme LLC submitted a request to the Foreign-Trade Zones (FTZ) Board on October 18, 2024, to start production activities at its facility in Rahway, New Jersey, which is part of FTZ Subzone 49Y. The FTZ Board reviewed this request and announced in the Federal Register that public comments on the activity were welcome. On February 18, 2025, the FTZ Board decided that no further review was necessary and approved the proposed production activities, as long as they comply with FTZ regulations. This authorization was communicated to the applicant on the same day.

Sanofi US Services Inc. has asked the Foreign-Trade Zones Board for permission to start production of pharmaceutical products at its facilities in Ridgefield, New Jersey, within FTZ 49. Specifically, they plan to produce Beyfortus® (Nirsevimab), a vaccine that will be duty-free. The materials needed for this production also include the duty-free Beyfortus® monoclonal antibody active ingredient. The public is invited to comment on this proposal by February 18, 2025, by sending an email to the Board's Executive Secretary.

Celgene Corporation has notified the Foreign-Trade Zones (FTZ) Board about its proposed manufacturing activities in Warren and Summit, New Jersey. The notification seeks permission for these locations to operate under FTZ 49 to produce cell therapy products, allowing Celgene to avoid customs duties on certain foreign materials used in products destined for export. The company may also reduce or defer duties on foreign equipment and scrap. Public comments are invited until April 6, 2021, and further details can be obtained by contacting the FTZ Board.

Phillips 66 Company has submitted a notification for proposed production activity at its facility in Linden, New Jersey, under Foreign-Trade Zone Subzone 49E. The proposal includes plans to produce renewable energy products like Renewable Diesel, Sustainable Aviation Fuel, Renewable Naphtha, and Renewable Gasoline. Public comments on this proposal are encouraged and must be submitted by April 15, 2025, to the Foreign-Trade Zones Board’s Executive Secretary. More details on the proposal can be accessed through the Board’s website, and inquiries can be directed to Luke Engan.

Merck, Sharp & Dohme LLC has informed the Foreign-Trade Zones (FTZ) Board about proposed production activities at their Rahway, New Jersey, facility, which is part of Subzone 49Y. The proposal includes producing drugs for metabolic and immunological disorders using specific foreign-sourced materials. Interested parties can submit their comments to the FTZ Board by February 24, 2025. More details and the notification can be accessed on the Board's website.

Merck, Sharp & Dohme LLC has submitted a proposal to the Foreign-Trade Zones Board for a production activity in their Rahway, New Jersey facility, which is part of Foreign-Trade Zone 49. The proposal outlines plans to manufacture various pharmaceutical products, including drugs for infectious and neurologic diseases, oncology, immunotherapy, and cardiovascular disease, using foreign materials. Some of these materials are subject to specific trade regulations depending on their country of origin. Public comments on the proposal are welcome until May 27, 2025, and those interested in more information can contact the Board or access documents on their website.

Merck, Sharp & Dohme LLC submitted a proposal to the Foreign-Trade Zones Board to conduct production activities at its facility in Rahway, New Jersey. The request was reviewed according to the Board's regulations, and the public was invited to comment. On January 16, 2024, the Board decided no further review was needed, and the production activity was authorized under existing regulations. The notification was officially documented on January 16, 2025.